Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
Sponsor: University of Colorado, Denver
Summary
Levetiracetam (LEV: (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is an anticonvulsant/antiepileptic drug. The specific aim of this study is to assess the efficacy of low-dose LEV in reducing hippocampal activity in schizophrenia. The investigators also hypothesize that LEV will improve neurocognition in participants with schizophrenia.
Official title: Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2013-06
Completion Date
2024-09
Last Updated
2026-08-21
Healthy Volunteers
No
Conditions
Interventions
Levetiracetam
Placebo
Locations (1)
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States